Follow on TwitterFDA Considers Permitting Popular Prescriptions To Be Sold Over-The-Counter
In an effort to make medications more easily available to Americans, the FDA may allow prescription drugs which combat chronic illnesses, such as high cholesterol, diabetes, asthma, and migraine headaches, to be purchased over-the-counter (OTC).
The FDA outlined the rationale behind its proposal:
Getting medicines into the hands of consumers has become troublesome over the last few years. Research shows that for a variety of reasons, 20 percent of patients with prescriptions do not get them filled. In addition, the time or cost required visiting a doctor to receive a prescription or refill often stops patients.
The Food and Drug Administration thinks that some of these doctor visits can be eliminated. It is exploring ways to make drugs for common conditions available as nonprescription products. Under this paradigm, the agency would approve drugs — that would otherwise require a prescription — for over-the-counter (OTC) distribution, if certain conditions are followed.
The agency is presently in an exploratory phase, encouraging input from all stakeholders, including doctors, pharmaceuticals, insurers, pharmacists, and patients.
It should come as no surprise that the move has pitted two powerful interest groups against one another: BigPharma, who stands to gain direct access to millions of consumers, and doctors, who stand to lose a lot of office visits, and their corresponding fees, for writing prescriptions and their refills.
Pharmaceutical companies have long complained that the restrictions placed upon them in getting their medications into the hands of those who need them is more cumbersome in the U.S. than anywhere else in the world.
For example, as early as 2004, the U.K. reclassified low-doses of a commonly used statin (generic: Simvastatin 10mg) from prescription drug to OTC drug. Statins lower cholesterol levels in the blood, thereby helping to prevent strokes and heart disease. Higher doses, however, continue to require prescriptions since the potential for serious side-effects, including liver or muscle damage, increases with the dosage.
But regardless of the dosage, all statins sold in the U.S. still require prescriptions. Why is easy access to drugs like statins so important? Reuters reports:
About one in three U.S. adults has high blood pressure, which contributes to heart disease and stroke. The condition cost the United States about $76 billion in 2010, according to the Centers for Disease Control and Prevention.
The FDA said about a third of those with high blood pressure stop taking their medication.
The FDA is hoping to knock down the barriers that discourage these millions of Americans from taking their life-saving prescriptions.
BigPharma is obviously ecstatic about the prospects of circumventing the gatekeepers that stand between them and the public. The industry spends tens of billions of dollars ‘enticing’ doctors to prescribe their medications. A 2008 study in PLoS Medicine found that pharmaceutical companies spend an average of US $61,000 per physician per year, on physician-targeted promotions.
Doctors, however, contend that patient consultation is essential for managing chronic conditions. This Sunday, In a USA Today op-ed, American Medical Association president Peter Carmel panned the new FDA effort, by defending the physician’s role, as well as by questioning the projected cost benefits:
As a chronic condition evolves, treatment changes are often needed from a physician. Without physician involvement, patients might take the wrong medication or dose for their needs, potentially causing harm. Self-diagnosis and treatment conflict with the care coordination and disease management that new health care payment and delivery models are trying to achieve.
Contrary to claims that this will save patients money, out-of-pocket costs for insured individuals, including those under Medicare, would increase for drugs switched from prescription to OTC status because patients would need to cover the entire cost themselves. Higher costs would make it harder for patients to afford the medication they need.
But the FDA envisions pharmacists assuming more of the medication consultation responsibilities, presently reserved for physicians. And pharmacist groups have lined up in support of the FDA proposal, including the American Pharmacists Association (APA), the National Community Pharmacists Association, the Academy of Managed Care Pharmacy, and the National Association of Boards of Pharmacy.
The FDA also plans to take advantage of new technological advancements. Its present OTC rules were written in a time when access to information technology did not exist. But today, the agency envisions utilizing consumer interactive mechanisms (through the internet and touch-screen kiosks at pharmacies), and incorporating electronic health record information, e-prescriptions, patient portals — all of which could effectively link pharmacy, patients and providers in a dramatically new way.
The FDA does, however, acknowledge several potential roadblocks to its proposal, including Carmel’s point above, regarding the insurance industry’s current non-reimbursement policy for OTC drugs. Other potential roadblocks mentioned, include “liability concerns, disruption of workflow for often overburdened pharmacists, [and] equipment costs.”
Here is how a new OTC policy might work (as outlined by the FDA):
To ensure safe and appropriate use, special conditions would apply to types of nonprescription products. For example, before getting a medication, you might have to talk with a pharmacist, or need to have a diagnostic test. In other cases, you might have to visit a physician to obtain the original prescription, but not to get refills. FDA is also considering whether some drugs could be a prescription drug and a nonprescription drug with conditions of safe use.
Various technologies could support this model. Kiosks in pharmacies or questionnaires on the Internet could help consumers properly diagnose a health condition and select a drug product. Such types of systems could also help consumers decide if the warnings for a drug mean that they should not take a drug or they should not combine it with certain other drugs or foods.
Another scenario for enhancing self-care could involve pharmacists that could help consumers verify their diagnosis, or decide whether the medication is right.
“Pharmacists could also reinforce directions for use,” said Woodcock.
There are a number of potential benefits for consumers from this initiative: an increase in the appropriate use of medication, decreases in health costs, greater access to health screening, easier access to needed medications, and better, more consistent treatment of common conditions.
Though there are still significant hurdles to overcome — the insurance industry’s non-reimbursement policy for OTC drugs would likely make this proposal a “no go” for all Americans — I applaud the FDA’s attempts to confront some rather obvious inefficiencies in the system.
Many Americans with chronic illnesses cannot afford office visits to a doctor, much less repeat visits, for the sole purpose of having prescriptions filled or refilled. Others cannot take off from work each and every time they need a refill, so that a doctor can write out another prescription.
Barriers, like these, discourage millions of Americans from getting the medications they need to treat serious chronic diseases, and as a result, they often end up in the ER in critical condition. This is not good for our citizenry’s health, and it only exacerbates our nation’s runaway healthcare costs.
VIDEO: Green Party Presidential Candidate Jill Stein Explains Her Green New Deal To Thom Hartmann
The following is last night’s Thom Hartmann interview with 2012 Green Party candidate for President, Dr. Jill Stein.
In it, Stein breaks down her FDR-style Green New Deal, her reasons for transitioning from medical doctor to politics, and why America is now ripe for a third party, like the Green Party, whose policy positions, unlike the two major parties, offer real solutions to fix America’s problems.
For those who prefer to read (rather than watch), or for whom English is a second language, I transcribed the first part of the interview. The video interview, in its entirety, follows:
Stein:
As you know, we’ve got about 25 million people now who need a full-time job. And of them, about five-and-a-half million, or so, have been unemployed for well over a year, or a year-and-a-half. So we have really got this ingrained, entrenched problem. We need a solution to actually rise to the magnitude and the seriousness — the emergency — of this jobs problem.
So the Green New Deal is exactly that. It is modeled after the New Deal that helped get us out of the Great Depression. So it would be basically 25 million jobs that would be created to put people back to work, to end unemployment, and thereby eliminate, put an end to, the recession — at the same time that we transition quickly to a secure green economy for the 21st Century; at the same time we create a secure energy supply.
What’s not to love about this? It’s sort of motherhood and apple pie.
Hartmann:
Well, but that’s kind of broad brush strokes. What are the specifics?
Stein:
Technically, there are four pieces to the Green New Deal. There is a full-employment program that also comes with an economic bill of rights, that also ensures that everyone has a right to, and will have, health care as a human right, education through college, etc, affordable housing …
Hartmann:
Sounds like Franklin Roosevelt’s second bill of rights.
Stein:
Exactly. The name ‘New Deal’ is not a coincidence. It is very much inspired by what FDR did. It had a dramatic impact on the economy, and we need that every bit as much now. The President’s plans have aimed for 2 million jobs, or 3 million jobs. And they’ve sort of come and gone, and those jobs packages have relied a lot on tax breaks which are non-specific. They don’t really get the job done.
So, this specifically would provide the funding to ensure that everyone is back to work. It is estimated to cost about what the stimulus package cost the first time around in 2008. About $700 billion, or thereabouts. But the impact would not be 2 million jobs, or 3 million jobs, but rather 25 million jobs. It would also include financial reform as well as a series of democracy reforms, which clearly we need, if we are going to be able to implement these economic reforms.
But getting to the jobs piece, because that is really what is, I think, front and center in most peoples’ minds. That’s really where the urgent need is. So focusing on that, what the Green New Deal would do would be able to basically create jobs in the areas of the new green economy; to create sustainable communities and thriving local economies.
So what does that mean? That means jobs in typically green areas, like in green renewable energy, in public transportation, in clean manufacturing, and also in local and sustainable agriculture.
So these are sort of the pillars of it. In addition, it would include also jobs that would make our communities socially sustainable. That ensures that we have teachers, and that we have child care, and senior care workers, and after school workers, and so on. It would begin to fill the critical needs. We have people who are willing and able to do the work.
We can redirect funds instead of to wars, Wall Street, and tax breaks for the wealthy. We can redirect that money. There is enough to put, basically invest in our economy to be able to solve the economic problem at the same time that we solve our environmental emergencies.
Hartmann:
… Who is Jill Stein?
Stein:
I am a Medical Doctor by training, that discovered that there were a lot of problems with our health care system, and actually with our health. But that we were neglecting the very simple cost-effective solutions up front. As well as neglecting a win-win Medicare-for-all, single-payer-type health care system that could actually provide the care that people need.
So, as a Medical Doctor, early in my practice, I saw the health care system really failing us. I thought, “Gee, I’m a doctor, I’ll be a public advocate, I will talk to my Legislators.” And, you know, you start doing that, and you learn pretty quickly that if we want to fix the things that are broken — the health care we need, the jobs we need, the healthy communities we need, the schools, you name it — if we want to fix those problems, we have to first fix the political system, which is terribly broken, and unfortunately is being run by the foxes in charge of the chicken coup, here.
And I’d say that over two decades, really, of advocacy, I’d only seen us backslide and backslide to where I began to feel that instead of being a doctor of health care, in the clinic, I needed to move up and be a doctor of politics, which is what I talk about now. Talking about political medicine, because it is sort of the mother of all illnesses at this point. You’ve got to fix that one in order to fix the other ones.
WATCH:
[youtube]http://www.youtube.com/watch?v=asqKKrXLxhY[/youtube]
You can learn more about Jill Stein and her positions on a whole host of issues at her website, or by following her on Twitter.
A Case For Scrapping Drug Patent Monopolies As Incentive For R&D
It is widely accepted across the gamut of economic ideologies that when a monopoly exists a free marketplace becomes inefficient and fails. It fails, because without competition, a monopolist is all but guaranteed to price-gauge consumers. So it’s no wonder that US anti-trust laws were written to safeguard the marketplace from monopolistic (anti-competitive) behavior.
Yet, for over half-a-century, the idea that the pharmaceutical industry should somehow remain exempt from this monopolistic prohibition, has largely gone unquestioned. By being permitted to patent its medicines, BigPharma enjoys a monopoly in the marketplace for a fixed period (20 years or more per drug), where they are free to price-gauge consumers.
The rationale behind drug patent monopolies rests upon the idea that without huge profits assured by this 20+ year price-gauging period, these pharmaceuticals would lack the incentive to invest in costly research and development. In addition, the actual manufacturing of medication tends to be cheap, so without patent-protection would-be-competitors, unburdened by R&D investments, could easily sell many generics for as low as $10 per prescription.
And thus, the drug patent has been widely accepted as a necessary evil.
But by choosing patenting as the preferred incentive for private R&D investment, the government is knowingly handing ‘for-profit’ corporations monopolistic licenses over vital consumer products.
We are not talking about discretionary goods, here — music downloads, books, or software — which people can live without. We’re talking about medicines that often keep people alive, or help to lessen their pain and suffering. In other words, the consumer CANNOT DO WITHOUT many of these products. And the provider, being shielded from competition, is well-positioned to take full advantage of their desperation.
Which is why the Pharmaceutical industry consistently ranks as one of the most profitable industries in the United States.
In response to public outrage over the fact that drug prices consistently rise at a much faster pace than the rate of inflation, the Congressional Budget Office (CBO) conducted a study in 2006 to assess the industry’s R&D expenses.
The study revealed that Federally-funded research has played a HUGE role in the discovery of nearly all new drugs released by the pharmaceutical industry. In fact, the only industry that receives more Federal subsidies for R&D is defense.
Here were some of the CBO’s findings:
- The federal government expended $25 billion on health-related R&D in the previous year alone (2005).
- “Most of the important new drugs introduced by the pharmaceutical industry over the past 40 years were developed with some contribution from public-sector research.”
- “Out of 21 of the most influential drugs introduced between 1965 and 1992, only five were essentially developed entirely by the private sector.”
- “In the past decade, federal outlays on health-related research and development have totaled hundreds of billions of dollars at the National Institutes of Health (NIH) alone.”
- R&D costs for new drugs are usually low, because more often than not, they are merely incremental modifications of already existing drugs.
CBO reported that the amount BigPharma itself contributes towards R&D is a staggering $800 million (2006 dollars) on average per drug release. However, CBO pulled these numbers from a separate study conducted by Tufts Center for the Study of Drug Development, which happens to be financed by — you guessed it — BigPharma itself!
In fact, a recent study published in the journal BioSocieties, entitled “Demythologizing the High Costs of Drug Research,” by Donald W. Light of the University of Medicine and Dentistry of New Jersey and Rebecca Warburton of the University of Victoria, took a hard look at those Tuft numbers. And what they found were HUGE flaws (Note: some of the major flaws are summarized HERE at Slate) which dramatically inflated BigPharma’s R&D costs:
When Light and Warburton correct for all these flaws—well, all the ones that can be quantified—they end up with an average cost of bringing a drug to market that’s $59 million and a median cost that’s $43 million. In 2011 dollars, that’s a $75 million average and a $55 million median.
So the drug companies’ [last stated] $1.32 billion estimate was off, according to Light and Warburton, by only $1.265 billion.* Let’s call it a rounding error.
Therefore, it appears the only credible information that can be gleaned from the CBO study is the taxpayer-funded portion of pharmaceutical R&D, and it is HUGE (to the tune of hundreds of billions of dollars).
A 2008 study entitled “The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States,” published by the Public Library of Science, estimated that BigPharma spends nearly twice as much on advertising and promotion than it does on R&D expenditures, contrary to the industry’s claim. Their research reveals that the US pharmaceutical industry is in fact marketing-driven, despite its constant claims that it is research-driven.
In January, BusinessWire published “2011 Trends to Watch in Pharmaceutical Technology” which reported that BigPharma plans to cut R&D costs in 2011, by outsourcing their R&D operations to emerging markets, like China and India.
The CEO of GlaxoSmithKline just announced he’s been aggressively closing R&D operations, and instead partnering with academic research centers (again, government funded) & biotech companies:
One of the more vocal voices in the changing R&D landscape has been GlaxoSmithKline (GSK) CEO Andrew Witty. His company has significantly pared down its fixed R&D costs by closing research facilities, doing less discovery work internally, and pushing more and more responsibility for research to external academic and biotech partners.
It’s the same familiar theme that has come to define much of corporate America: socializing much of the risks and costs, outsourcing the higher-paying technical jobs to low-cost-labor countries, privatizing all the profits, and then evading paying US income taxes (as this Bloomberg article highlights).
Except in this case, the government additionally grants BigPharma a 20+ year competition-free environment with which to fleece the American people, to the detriment of their wallets, their health and their lives.
The US obviously needs to find a new creative way to ensure that financial incentives for private R&D remains, but without granting corporations monopolist-licenses to harm the public. Drug patent monopolies make no economic sense, and have proven to be a resounding failure on every front.
A couple months ago, Vermont Senator Bernie Sanders proposed a major reform bill of the drug patent system that sounds like a winning strategy. The bill would essentially replace drug monopolies with prizes:
He has introduced a bill to create a prize fund that would buy up patents, so that drugs could then be sold at a free market price. Sanders’s bill would appropriate 0.55% of GDP (about $80bn a year, with the economy’s current size) for buying up patents, which would then be placed in the public domain so that any manufacturer could use them at no cost.
This money would come from a tax on public and private insurers. The savings from lower-cost drugs would immediately repay more than 100% of the tax.
The country is projected to spend almost $300bn a year on prescription drugs this year. Prices would fall to roughly one-tenth this amount in the absence of patent monopolies, leading to savings of more than $250bn. The savings on lower drug prices should easily exceed the size of the tax, leaving a substantial net reduction in costs to the government and private insurers.
This would help to bolster R&D investment, by ensuring these firms are handsomely rewarded with all-upfront payouts for their products, which they could then reinvest into their R&D operations. Their huge marketing budgets would evaporate, thus saving them the lion-share of their current expenses. And at the same time, it would inject competition into the drug manufacturer marketplace — essential for ensuring these products remain widely available and affordable to the consumer.
And equally important, it would substantially impact our nation’s runaway healthcare costs by reducing our $300 billion annual pharmaceutical expenditures down to $30 billion. This would help to shore up Medicare and Medicaid, save lives, and put more money back into the pockets of the American people.
Here Comes The Pain: Two-thirds of States Cut Mental Health Care Funding
Despite an increase in our nation’s mental health care needs due to tens of millions of Americans having lost their jobs, and tens of thousands of military personnel returning home from war, the National Alliance on Mental Illness (NAMI) is reporting that two-thirds of states are making deep cuts to their mental health care programs. […]
This November, Write-In “Public Option”
I met up with Stan at The Seminal at FireDogLake (FDL). I’d recently written about the rationality of we on the Left strategically boycotting the upcoming midterm elections, and had continued pushing that notion in the comments of a diary by Democratic Party flack Jason Rosenbaum, seeking help in those elections from we who had given his co-opted little party […]
A Final Nail In The Public Option Coffin: Nancy Pelosi
The Democratic Party’s betrayal of the Left is effectively complete: Speaker Pelosi (D-Calif.) showed flexibility Tuesday on the public option, acknowledging the political reality that such a plan probably couldn’t make it through the Senate. A public plan, Speaker Pelosi said at a press conference, is meant to “hold insurance companies accountable and increase competition,” […]
PLEASE Sign! EMERGENCY Petitions To Save The Public Option!
Petition to HARRY REID: “Don’t let the Baucus bill kill the public option.” SIGN HERE: CREDO Action Petition to PRESIDENT OBAMA: “Every day, insurance companies deny care and let people die. Getting one Republican senator’s vote is not worth delaying reform — too many real lives are at stake. We need you to fight and […]
The Status Quo And How Washington Ensures It
A major impasse appears to exist these days between Democrats and Republicans on virtually every issue. On the surface, it would seem it’s all ideology-based. But upon closer inspection, their hostilities are, in large part, incited by media-manufactured outrage, where partisan vitriol and ideological demagoguery drowns out all thoughtful discourse. Unfortunately, our country is in […]
Follow AlterPolitics on Twitter
